IL285910A - Use of vibegron to treat overactive bladder - Google Patents

Use of vibegron to treat overactive bladder

Info

Publication number
IL285910A
IL285910A IL285910A IL28591021A IL285910A IL 285910 A IL285910 A IL 285910A IL 285910 A IL285910 A IL 285910A IL 28591021 A IL28591021 A IL 28591021A IL 285910 A IL285910 A IL 285910A
Authority
IL
Israel
Prior art keywords
vibragron
overactive bladder
treat overactive
treat
bladder
Prior art date
Application number
IL285910A
Other languages
English (en)
Hebrew (he)
Inventor
Jr Paul N Mudd
Original Assignee
Urovant Sciences Gmbh
Jr Paul N Mudd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urovant Sciences Gmbh, Jr Paul N Mudd filed Critical Urovant Sciences Gmbh
Publication of IL285910A publication Critical patent/IL285910A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL285910A 2019-03-18 2021-08-26 Use of vibegron to treat overactive bladder IL285910A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962820230P 2019-03-18 2019-03-18
US201962830302P 2019-04-05 2019-04-05
US201962842435P 2019-05-02 2019-05-02
US201962885767P 2019-08-12 2019-08-12
US201962897019P 2019-09-06 2019-09-06
US201962904429P 2019-09-23 2019-09-23
PCT/IB2020/052484 WO2020188505A1 (en) 2019-03-18 2020-03-18 Use of vibegron to treat overactive bladder

Publications (1)

Publication Number Publication Date
IL285910A true IL285910A (en) 2021-10-31

Family

ID=70166082

Family Applications (1)

Application Number Title Priority Date Filing Date
IL285910A IL285910A (en) 2019-03-18 2021-08-26 Use of vibegron to treat overactive bladder

Country Status (14)

Country Link
US (1) US20230027066A1 (cg-RX-API-DMAC7.html)
EP (2) EP4763281A2 (cg-RX-API-DMAC7.html)
JP (2) JP2022524576A (cg-RX-API-DMAC7.html)
KR (2) KR20260049872A (cg-RX-API-DMAC7.html)
CN (2) CN121489955A (cg-RX-API-DMAC7.html)
AU (2) AU2020243514A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021017198A2 (cg-RX-API-DMAC7.html)
CA (1) CA3129024A1 (cg-RX-API-DMAC7.html)
IL (1) IL285910A (cg-RX-API-DMAC7.html)
MX (1) MX2021009488A (cg-RX-API-DMAC7.html)
PH (1) PH12021551975A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202108810YA (cg-RX-API-DMAC7.html)
TW (2) TW202506129A (cg-RX-API-DMAC7.html)
WO (1) WO2020188505A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250099259A (ko) 2017-06-06 2025-07-01 유로반트 사이언시즈 게엠베하 과민성 방광의 치료를 위한 비베그론의 용도
TW202038963A (zh) 2018-12-05 2020-11-01 瑞士商優洛凡特科學公司 維貝隆(vibegron)於治療患有良性前列腺增生之男性中膀胱過動症症狀之用途
TW202245781A (zh) * 2021-02-16 2022-12-01 瑞士商優洛凡特科學公司 用維貝格龍(vibegron)治療心臟衰竭之方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
WO2013062881A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
JP6383403B2 (ja) 2013-03-15 2018-08-29 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. β−3作動薬および中間体の製造方法
JP6197971B1 (ja) * 2016-04-22 2017-09-20 小野薬品工業株式会社 Kcnq2〜5チャネル関連疾患の予防および/または治療剤
WO2017210696A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder
US10057209B2 (en) * 2016-07-28 2018-08-21 Qualcomm Incorporated Time-sequenced multi-device address assignment
KR20250099259A (ko) * 2017-06-06 2025-07-01 유로반트 사이언시즈 게엠베하 과민성 방광의 치료를 위한 비베그론의 용도
CN110869053A (zh) * 2017-06-06 2020-03-06 乌洛万特科学有限公司 给药维贝隆以治疗膀胱过度活动症
EP3583905A1 (en) * 2018-06-20 2019-12-25 Arthrex Inc Percutaneous targeting device

Also Published As

Publication number Publication date
TW202102221A (zh) 2021-01-16
AU2025256180A1 (en) 2025-11-13
JP2022524576A (ja) 2022-05-09
US20230027066A1 (en) 2023-01-26
KR20260049872A (ko) 2026-04-14
BR112021017198A2 (pt) 2021-11-16
EP3941473A1 (en) 2022-01-26
EP4763281A2 (en) 2026-06-24
WO2020188505A1 (en) 2020-09-24
AU2020243514A1 (en) 2021-08-26
SG11202108810YA (en) 2021-10-28
CA3129024A1 (en) 2020-09-24
PH12021551975A1 (en) 2022-07-04
CN121489955A (zh) 2026-02-10
CN113840607A (zh) 2021-12-24
MX2021009488A (es) 2021-09-21
KR20210142004A (ko) 2021-11-23
TW202506129A (zh) 2025-02-16
JP2025084777A (ja) 2025-06-03

Similar Documents

Publication Publication Date Title
IL285662A (en) Use of cannabinoids in the treatment of epilepsy
IL283372A (en) Use of cannabinoids in the treatment of epilepsy
IL284758A (en) Use of cannabinoids in the treatment of comorbidities associated with epilepsy
IL286888A (en) Use of pridopidine to treat depression or anxiety
IL271164A (en) Use of vibegron to treat overactive bladder
IL290780A (en) Rip1 inhibitory compounds and methods for making and using the same
IL283042A (en) Compounds and compositions for treating conditions associated with nlrp activity
IL263510A (en) Use of myostatin inhibitors and combination therapies
IL304733A (en) Improved use of botulinum neurotoxin in the treatment of sialorrhea
EP3609575A4 (en) PHOTOBIOMODULATION THERAPY TO REDUCE THE EFFECTS OF FIBROMYALGIA
LT4331584T (lt) Lanifibranoro deuterintų darinių terapietiniai naudojimai
PL3429571T3 (pl) Kombinacje inhibitorów lsd1 do zastosowania w leczeniu chorób nowotworowych
IL281927A (en) Combination therapy for melanoma
EP3536320A4 (en) APPLICATION OF A HEDGEHOG TRACT INHIBITOR FOR THE TREATMENT OF FIBROTIC DISEASES
IL283069A (en) Methods for administering corticosteroids
IL287904A (en) Combination treatment of arthritic disease
IL255557B (en) Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations
EP3934632A4 (en) Esketamine for the treatment of depression
IL292502A (en) Therapeutic methods using vadadustat
IL270900A (en) Treatment of cutaneous disorders
PL3697399T3 (pl) Środki terapeutyczne do zastosowania w leczeniu zespołu niespokojnych nóg
IL280343A (en) Treatment of mucopolysaccharidosis iva
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
IL291424A (en) Use of dkk-1 inhibitors for treating cancer
DK3390448T3 (da) Intravesikal terapi af blærekræft